Keep pulling the thread on Dr. Dan Barouch & Kris Brown.
The Riovax rhesus adenoviral vector platform is expected to have an efficacy advantage over human adenoviral platforms because there is no pre-existing baseline immunity to the rhesus vectors in the human population.
The Riovax platform's p7 protein lacks the key epitopes linked to the thrombosis side effect seen in other adenoviral vaccines, which is expected to provide a safety advantage.
In a comparative study, Vector Sciences' influenza vaccine candidate was shown to be significantly superior to both currently marketed flu vaccines and Pfizer's Phase 3 mRNA-based influenza vaccine candidate.
Vector Sciences' Riovax platform is built on rhesus adenovirus vectors.
The rhesus adenovirus platform developed by Vector Sciences is intended to improve upon prior adenovirus platforms by providing enhanced efficacy and safety features.
Kris Brown believes the Trump and Biden administrations mischaracterized COVID-19 shots as traditional vaccines, when they should have been described as treatments that protect against death but not necessarily infection.
The Riovax platform, developed by Vector Sciences, is designed for mucosal delivery, such as through nasal inhalation.
The AstraZeneca and Johnson & Johnson COVID-19 vaccines caused a thrombosis side effect in approximately 3 out of one million cases.
The rare thrombosis side effect associated with some adenoviral vaccines is believed to be caused by cross-reactivity of the adenovirus p7 protein, which leads to antibodies that bind to the human coagulation protein platelet factor 4.
According to the CDC, the influenza vaccine has demonstrated an effectiveness of 19% to 60% over the last 20 years.
In experimental models, mucosal delivery of the Rhesus Ad Platform has led to substantially improved protection against pathogens such as COVID-19 and influenza.
The Riovax platform does not require a cold chain for distribution and can be lyophilized into a powder form, making it easier to store and administer.